Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777434 | 1.00 | CD274 (0.45) | CD274ALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL16554640 | 0.84 | CD274 (0.55) | CD274ALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3181728 | 0.82 | DPP4 (0.60) | CD274ALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL28148661 | 0.82 | CD274 (0.45) | CD274ALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL3644296 | 0.81 | ESR2 (0.40) | ALDH1A1SMN1; SMN2CYP1A2ADRA2C | |
| SCHEMBL12679716 | 0.80 | ALDH1A1 (0.52) | CD274ALDH1A1KDM4EMAPK1L3MBTL1 | |
| SCHEMBL2809185 | 0.80 | CYP1A2 (0.39) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL21367487 | 0.79 | CD274 (0.58) | CD274 | |
| SCHEMBL29210714 | 0.79 | KDM4E (0.47) | CD274ALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL2575063 | 0.79 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPK1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271246-A | Method for continuously preparing 2-butyl-1, 3-diazaspiro [4.4] nonane-1-en-4-one | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-115215813-A | Method for controlling valsartan impurity | 江苏新瑞药业有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-108732279-B | Method for analyzing and determining genotoxic impurities in valsartan by using HPLC (high performance liquid chromatography) method | 齐鲁制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-108732279-A | A method of it is analyzed using HPLC methods and measures genotoxicity impurity in Valsartan | 齐鲁制药有限公司 | 2018-11-02 | — | — | CN | claimed |
| CN-114436833-B | Preparation method of telmisartan key intermediate 4' -bromomethyl biphenyl-2-carboxylate | 南京红太阳医药研究院有限公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-118271246-A | Method for continuously preparing 2-butyl-1, 3-diazaspiro [4.4] nonane-1-en-4-one | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| CN-115215813-A | Method for controlling valsartan impurity | 江苏新瑞药业有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-108732279-B | Method for analyzing and determining genotoxic impurities in valsartan by using HPLC (high performance liquid chromatography) method | 齐鲁制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-108732279-B | Method for analyzing and determining genotoxic impurities in valsartan by using HPLC (high performance liquid chromatography) method | 齐鲁制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114436833-A | Preparation method of telmisartan key intermediate 4' -methylbiphenyl-2-carboxylic ester | 南京红太阳医药研究院有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2008062905-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007026375-A1 | PROCESS FOR THE PREPARATION OF LOSARTAN | SUVEN LIFE SCIENCES (IN) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007013101-A1 | PROCESS FOR PRODUCING 2-(N-BUTYL)-3-[[2'-(TETRAZOL-5-YL)BIPHENYL- 4-YL]METHYL]-l,3-DIAZASPIRO[4.4] NON-1-EN-4-ONE | JUBILANT ORGANOSYS LIMITED (IN) | 2007-02-01 | — | — | WO | disclosed |
| EP-1019048-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | Merck Sharp Dohme (Italia) S.P.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999033788-A2 | METHOD FOR PRODUCING AROMATIC BROMOMETHYL BIPHENYL COMPOUNDS | GREAT LAKES CHEMICAL KONSTANZ GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999016437-A1 | USE OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREPARATION OF DRUGS TO INCREASE THE SURVIVAL RATE OF RENAL TRANSPLANT PATIENTS | MERCK SHARP DOHME (ITALIA) S.P.A. (IT) | 1999-04-08 | — | — | WO | disclosed |
| US-5369114-A | Angiotensin II antagonist | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-11-29 | — | — | US | disclosed |
| EP-0456442-A1 | Quinoline derivatives, process for their preparation and their use as medicaments | ZENECA LIMITED (GB) | 1991-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | CD274 1/4885ALDH1A1 86/4885KDM4E 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.